Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors

Radiation Oncology

Table 1 Biodistribution of carboplatin in F98 glioma bearing rats following CED in either untreated or dexamethasone, mannitol, and furosemide treated rats ^a

	Carboplatin concentration (μg/g tissue)^b
Animal no.	Untreated			DMF treated
	Tumor	R Brain	L Brain	Tumor	R Brain	L Brain
1	3.02	1.41	1.35	8.55	1.63	1.01
2	6.34	0.82	0.45	10.16	1.22	0.78
3	7.92	1.55	1.00	10.63	1.83	1.12
4	8.15	1.13	0.92	10.64	1.79	0.83
5	8.84	1.62	0.88	12.85	3.10	1.34
6	9.84	0.92	0.30	13.32	0.95	0.99
7	14.10	2.05	0.84	14.81	1.30	0.82
8	17.10	1.74	1.34	18.51	2.28	0.96
Mean ± SD^c	9.41 ±4.40	1.41 ±0.42	0.89 ±0.37	12.43 ±3.17	1.76 ±0.68	0.98 ±0.18
Median	8.50	1.48	0.90	11.75	1.71	0.98
Tumor: brain ratios		6.7:1	10.6:1		7.1:1	12.7:1

^aRats received either i.p. dexamethasone (D) (3 mg/kg b.v. daily for 3 days) or i.p. dexamethasone (D) followed by i.v. mannitol (M) (2.5 g/kg b.w.) at 0.25 ml/min over 10 min, followed 15 min later by i.v. furosemide (F) (2 mg/kg b.w.). Since the carboplatin values were equivalent, these were combined.
^bRats were euthanized at ~20 min following termination of CED, their brains removed, tumors dissected out, as well as the remainder of the tumor bearing right and non-tumor bearing left cerebral hemispheres. Platinum concentrations were determined by means of ICP-OES and then converted to carboplatin by multiplying by 1.9.
^cSD designates the standard deviation.

ISSN: 1748-717X